Laropiprant
Pelzont, Tredaptive, Trevaclyn (laropiprant) is a small molecule pharmaceutical. Laropiprant was first approved as Trevaclyn on 2008-07-03. It has been approved in Europe to treat dyslipidemias. It is known to target prostaglandin D2 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| dyslipidemias | HP_0003119 | D050171 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | 3 | 1 | 12 | 2 | 1 | 19 |
| Dyslipidemias | D050171 | HP_0003119 | — | 2 | 1 | 8 | 6 | 1 | 18 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | 1 | — | 6 | 2 | — | 9 |
| Hyperlipoproteinemias | D006951 | HP_0010980 | — | — | — | 6 | 2 | — | 8 |
| Familial combined hyperlipidemia | D006950 | EFO_0000492 | E78.49 | 1 | — | 3 | 1 | — | 5 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | 3 | — | 4 |
| Coronary disease | D003327 | — | — | — | — | 1 | 2 | — | 3 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | 2 | — | 3 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | 1 | 1 | — | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 1 | 1 | — | 2 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipoproteinemia type v | D006954 | Orphanet_70470 | E78.3 | 1 | — | 3 | — | — | 4 |
| Lipidoses | D008064 | — | E75.6 | — | — | 3 | — | — | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 2 | — | — | 2 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 1 | — | 1 | 2 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | 1 | — | 1 | 2 |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
| Flushing | D005483 | — | R23.2 | — | 1 | — | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
| Lipid metabolism disorders | D052439 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Laropiprant |
| INN | laropiprant |
| Description | Laropiprant (INN) was a drug used in combination with niacin to reduce blood cholesterol (LDL and VLDL) that is no longer sold, due to increases in side-effects with no cardiovascular benefit. Laropiprant itself has no cholesterol lowering effect, but it reduces facial flushes induced by niacin.
|
| Classification | Small molecule |
| Drug class | prostaglandin receptor antagonists, non prostinoid structure |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3 |
Identifiers
| PDB | — |
| CAS-ID | 571170-77-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL426559 |
| ChEBI ID | — |
| PubChem CID | 11948701 |
| DrugBank | DB11629 |
| UNII ID | G7N11T8O78 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 903 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
125 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use